Integer (ITGR) Scheduled to Post Earnings on Thursday

Integer (NYSE:ITGR) is set to release its earnings data before the market opens on Thursday, April 25th. Analysts expect Integer to post earnings of $1.12 per share for the quarter. Integer has set its FY24 guidance at $5.01-5.43 EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.05. Integer had a return on equity of 10.80% and a net margin of 5.68%. The firm had revenue of $413.15 million during the quarter, compared to the consensus estimate of $409.04 million. During the same period last year, the company earned $1.11 earnings per share. The company’s revenue was up 10.9% on a year-over-year basis. On average, analysts expect Integer to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Integer Price Performance

Shares of NYSE:ITGR opened at $118.49 on Thursday. Integer has a 1-year low of $69.40 and a 1-year high of $121.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71. The business has a fifty day moving average price of $111.36 and a 200-day moving average price of $98.08. The company has a market capitalization of $3.97 billion, a PE ratio of 44.05, a PEG ratio of 1.50 and a beta of 1.10.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ITGR. Bank of America raised Integer from a “neutral” rating to a “buy” rating and increased their price objective for the company from $105.00 to $135.00 in a research report on Monday. KeyCorp increased their price objective on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th. CL King initiated coverage on Integer in a research report on Thursday, March 14th. They issued a “buy” rating and a $137.00 target price on the stock. Finally, Benchmark raised their target price on Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.50.

Institutional Trading of Integer

A number of large investors have recently added to or reduced their stakes in ITGR. Raymond James & Associates increased its stake in Integer by 12.6% in the 1st quarter. Raymond James & Associates now owns 40,898 shares of the medical equipment provider’s stock worth $3,295,000 after acquiring an additional 4,578 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Integer by 1.3% during the 1st quarter. Bank of New York Mellon Corp now owns 406,645 shares of the medical equipment provider’s stock valued at $32,763,000 after purchasing an additional 5,256 shares during the last quarter. American Century Companies Inc. increased its position in shares of Integer by 20.9% during the 1st quarter. American Century Companies Inc. now owns 5,573 shares of the medical equipment provider’s stock valued at $449,000 after purchasing an additional 963 shares during the last quarter. US Bancorp DE increased its position in shares of Integer by 11.8% during the 1st quarter. US Bancorp DE now owns 9,970 shares of the medical equipment provider’s stock valued at $803,000 after purchasing an additional 1,051 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in shares of Integer by 2.9% during the 1st quarter. HighTower Advisors LLC now owns 7,831 shares of the medical equipment provider’s stock valued at $632,000 after purchasing an additional 217 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.